用于疫情防范的DNA疫苗：新冠病毒及其他。
DNA Vaccines for Epidemic Preparedness: SARS-CoV-2 and Beyond.
作者信息
Maslow Joel N, Kwon Ijoo, Kudchodkar Sagar B, Kane Deborah, Tadesse Amha, Lee Hyojin, Park Young K, Muthumani Kar, Roberts Christine C
机构信息
GeneOne Life Science, Inc., Seoul 04500, Republic of Korea.
Department of Medicine, Morristown Medical Center, Morristown, NJ 07960, USA.
出版信息
Vaccines (Basel). 2023 May 23;11(6):1016. doi: 10.3390/vaccines11061016.
Abstract
We highlight the significant progress in developing DNA vaccines during the SARS-CoV-2 pandemic. Specifically, we provide a comprehensive review of the DNA vaccines that have progressed to Phase 2 testing or beyond, including those that have received authorization for use. DNA vaccines have significant advantages with regard to the rapidity of production, thermostability, safety profile, and cellular immune responses. Based on user needs and cost, we compare the three devices used in the SARS-CoV-2 clinical trials. Of the three devices, the GeneDerm suction device offers numerous benefits, particularly for international vaccination campaigns. As such, DNA vaccines represent a promising option for future pandemics.
摘要
我们重点介绍了在新冠疫情期间DNA疫苗研发方面取得的重大进展。具体而言，我们对已进入2期试验或更后期阶段的DNA疫苗进行了全面综述，包括那些已获得使用授权的疫苗。DNA疫苗在生产速度、热稳定性、安全性和细胞免疫反应方面具有显著优势。根据用户需求和成本，我们比较了在新冠临床试验中使用的三种设备。在这三种设备中，GeneDerm吸引装置具有诸多优势，特别是对于国际疫苗接种运动。因此，DNA疫苗是未来应对大流行的一个有前景的选择。
相似文献
1
DNA Vaccines for Epidemic Preparedness: SARS-CoV-2 and Beyond.用于疫情防范的DNA疫苗：新冠病毒及其他。
Vaccines (Basel). 2023 May 23;11(6):1016. doi: 10.3390/vaccines11061016.
2
Safety and immunogenicity of the bi-cistronic GLS-5310 COVID-19 DNA vaccine delivered with the GeneDerm suction device.双顺反子 GLS-5310 COVID-19 DNA 疫苗与 GeneDerm 负压吸引器联合应用的安全性和免疫原性。
Int J Infect Dis. 2023 Mar;128:112-120. doi: 10.1016/j.ijid.2022.12.037. Epub 2022 Dec 31.
3
Preclinical safety assessment of the suction-assisted intradermal injection of the SARS-CoV-2 DNA vaccine candidate pGO-1002 in white rabbit.新型冠状病毒 DNA 疫苗候选物 pGO-1002 在新西兰白兔皮内注射的临床前安全性评估。
Arch Toxicol. 2023 Apr;97(4):1177-1189. doi: 10.1007/s00204-023-03446-y. Epub 2023 Jan 23.
4
Safety and immunogenicity following a homologous booster dose of a SARS-CoV-2 recombinant spike protein vaccine (NVX-CoV2373): a secondary analysis of a randomised, placebo-controlled, phase 2 trial.同源加强接种 SARS-CoV-2 重组刺突蛋白疫苗（NVX-CoV2373）的安全性和免疫原性：一项随机、安慰剂对照、2 期临床试验的二次分析。
Lancet Infect Dis. 2022 Nov;22(11):1565-1576. doi: 10.1016/S1473-3099(22)00420-0. Epub 2022 Aug 10.
5
Safety and immunogenicity of the SARS-CoV-2 ARCoV mRNA vaccine in Chinese adults: a randomised, double-blind, placebo-controlled, phase 1 trial.新型冠状病毒 ARCoV mRNA 疫苗在中国成年人中的安全性和免疫原性：一项随机、双盲、安慰剂对照、1 期临床试验。
Lancet Microbe. 2022 Mar;3(3):e193-e202. doi: 10.1016/S2666-5247(21)00280-9. Epub 2022 Jan 24.
6
Immune response enhancement with GLS-5310 DNA primary vaccine against SARS-CoV-2 followed by administration of an mRNA vaccine heterologous boost.GLS-5310 DNA 新冠病毒初级疫苗增强免疫反应，随后接种 mRNA 疫苗异源加强针。
Vaccine. 2023 Jun 29;41(29):4206-4211. doi: 10.1016/j.vaccine.2023.06.013. Epub 2023 Jun 6.
7
The Rapid Development and Early Success of Covid 19 Vaccines Have Raised Hopes for Accelerating the Cancer Treatment Mechanism.新冠疫苗的快速研发和早期成功为加速癌症治疗机制带来了希望。
Arch Razi Inst. 2021 Mar;76(1):1-6. doi: 10.22092/ari.2021.353761.1612. Epub 2021 Mar 1.
8
COVID-19 vaccines: concerns beyond protective efficacy and safety.COVID-19 疫苗：除了保护效力和安全性之外的关注点。
Expert Rev Vaccines. 2021 Aug;20(8):1013-1025. doi: 10.1080/14760584.2021.1949293. Epub 2021 Jul 5.
9
COVID-19 vaccines: comparison of biological, pharmacological characteristics and adverse effects of Pfizer/BioNTech and Moderna Vaccines.COVID-19 疫苗：辉瑞/生物科技和 Moderna 疫苗的生物学、药理学特征和不良反应比较。
Eur Rev Med Pharmacol Sci. 2021 Feb;25(3):1663-1669. doi: 10.26355/eurrev_202102_24877.
10
Insights into COVID-19 Vaccine Development Based on Immunogenic Structural Proteins of SARS-CoV-2, Host Immune Responses, and Herd Immunity.基于 SARS-CoV-2 的免疫原性结构蛋白、宿主免疫反应和群体免疫的 COVID-19 疫苗开发的新见解。
Cells. 2021 Oct 29;10(11):2949. doi: 10.3390/cells10112949.
引用本文的文献
1
Breaking barriers in the sensitive and accurate mass determination of large DNA plasmids by mass photometry.通过质量光度法在大型DNA质粒灵敏且准确的质量测定方面突破障碍。
Mol Ther Nucleic Acids. 2025 Jul 17;36(3):102632. doi: 10.1016/j.omtn.2025.102632. eCollection 2025 Sep 9.
2
A plant secretory sequence enhances immunogenicity of electroporated COVID-19 DNA vaccines.一种植物分泌序列可增强电穿孔新冠病毒DNA疫苗的免疫原性。
Front Med Technol. 2025 Jul 14;7:1597179. doi: 10.3389/fmedt.2025.1597179. eCollection 2025.
3
A modular mRNA vaccine platform encoding antigen-presenting capsid virus-like particles enhances the immunogenicity of the malaria antigen Pfs25.一种编码抗原呈递衣壳病毒样颗粒的模块化mRNA疫苗平台增强了疟疾抗原Pfs25的免疫原性。
Nat Nanotechnol. 2025 May 14. doi: 10.1038/s41565-025-01889-1.
4
Vaccination with Plasmids Encoding the Fusion Proteins D-S1, D-S1N and O-SN from SARS-CoV-2 Induces an Effective Humoral and Cellular Immune Response in Mice.用编码来自严重急性呼吸综合征冠状病毒2（SARS-CoV-2）的融合蛋白D-S1、D-S1N和O-SN的质粒进行疫苗接种可在小鼠中诱导有效的体液免疫和细胞免疫反应。
Vaccines (Basel). 2025 Jan 28;13(2):134. doi: 10.3390/vaccines13020134.
5
New insights for the development of efficient DNA vaccines.为开发高效的 DNA 疫苗提供新的见解。
Microb Biotechnol. 2024 Nov;17(11):e70053. doi: 10.1111/1751-7915.70053.
6
Vaccine skepticism and vaccine development stages; inoculation from "cowpox" lesion to the current mRNA vaccine of COVID-19: review.疫苗怀疑论与疫苗研发阶段；从“牛痘”损伤接种到当前的新冠mRNA疫苗：综述
Ther Adv Vaccines Immunother. 2024 Oct 11;12:25151355241288135. doi: 10.1177/25151355241288135. eCollection 2024.
7
COVID-19: vaccination, therapeutics and a review of the science and public health.2019冠状病毒病：疫苗接种、治疗方法以及科学与公共卫生综述
Ann Med Surg (Lond). 2024 Jul 17;86(9):5343-5353. doi: 10.1097/MS9.0000000000002374. eCollection 2024 Sep.
8
Opportunities and challenges to implementing mRNA-based vaccines and medicines: lessons from COVID-19.mRNA 疫苗和药物实施的机遇与挑战：从 COVID-19 中吸取的教训。
Front Public Health. 2024 Aug 8;12:1429265. doi: 10.3389/fpubh.2024.1429265. eCollection 2024.
9
DNA Vaccines: Their Formulations, Engineering and Delivery.DNA疫苗：其配方、工程设计与递送
Vaccines (Basel). 2024 Jan 11;12(1):71. doi: 10.3390/vaccines12010071.
本文引用的文献
1
Immunogenicity of COVID-eVax Delivered by Electroporation Is Moderately Impacted by Temperature and Molecular Isoforms.通过电穿孔递送的COVID-eVax的免疫原性受到温度和分子异构体的中度影响。
Vaccines (Basel). 2023 Mar 16;11(3):678. doi: 10.3390/vaccines11030678.
2
Investigating Generation of Antibodies against the Lipid Nanoparticle Vector Following COVID-19 Vaccination with an mRNA Vaccine.调查接种 mRNA 疫苗后针对脂质纳米颗粒载体产生的抗体。
Mol Pharm. 2023 Jul 3;20(7):3356-3366. doi: 10.1021/acs.molpharmaceut.2c01036. Epub 2023 Mar 23.
3
Preclinical safety assessment of the suction-assisted intradermal injection of the SARS-CoV-2 DNA vaccine candidate pGO-1002 in white rabbit.新型冠状病毒 DNA 疫苗候选物 pGO-1002 在新西兰白兔皮内注射的临床前安全性评估。
Arch Toxicol. 2023 Apr;97(4):1177-1189. doi: 10.1007/s00204-023-03446-y. Epub 2023 Jan 23.
4
Safety and immunogenicity of the bi-cistronic GLS-5310 COVID-19 DNA vaccine delivered with the GeneDerm suction device.双顺反子 GLS-5310 COVID-19 DNA 疫苗与 GeneDerm 负压吸引器联合应用的安全性和免疫原性。
Int J Infect Dis. 2023 Mar;128:112-120. doi: 10.1016/j.ijid.2022.12.037. Epub 2022 Dec 31.
5
A first-in-human trial on the safety and immunogenicity of COVID-eVax, a cellular response-skewed DNA vaccine against COVID-19.COVID-eVax，一种针对 COVID-19 的细胞反应偏向性 DNA 疫苗，人体首次安全性和免疫原性试验。
Mol Ther. 2023 Mar 1;31(3):788-800. doi: 10.1016/j.ymthe.2022.12.017. Epub 2022 Dec 27.
6
Reduced FVIII recovery associated with anti-FVIII PEG antibodies after BNT162b2 SARS-CoV-2 vaccination.BNT162b2新型冠状病毒疫苗接种后，抗FVIII PEG抗体导致FVIII回收率降低。
Blood Adv. 2023 Jan 10;7(1):174-177. doi: 10.1182/bloodadvances.2022008989.
7
Recent Advances in DNA Vaccines against Lung Cancer: A Mini Review.抗肺癌DNA疫苗的最新进展：一篇综述
Vaccines (Basel). 2022 Sep 21;10(10):1586. doi: 10.3390/vaccines10101586.
8
Phase I Study to Assess the Safety and Immunogenicity of an Intradermal COVID-19 DNA Vaccine Administered Using a Pyro-Drive Jet Injector in Healthy Adults.评估使用热驱动喷射注射器接种的皮内注射新冠病毒DNA疫苗在健康成年人中的安全性和免疫原性的I期研究。
Vaccines (Basel). 2022 Aug 30;10(9):1427. doi: 10.3390/vaccines10091427.
9
Anaphylaxis to Pfizer/BioNTech mRNA COVID-19 Vaccine in a Patient With Clinically Confirmed PEG Allergy.一名临床确诊对聚乙二醇过敏的患者对辉瑞/生物科技公司的mRNA新冠疫苗发生过敏反应。
Front Allergy. 2021 Sep 29;2:715844. doi: 10.3389/falgy.2021.715844. eCollection 2021.
10
Efficacy, safety, and immunogenicity of the DNA SARS-CoV-2 vaccine (ZyCoV-D): the interim efficacy results of a phase 3, randomised, double-blind, placebo-controlled study in India.DNA SARS-CoV-2 疫苗（ZyCoV-D）的有效性、安全性和免疫原性：在印度进行的 3 期、随机、双盲、安慰剂对照研究的中期疗效结果。
Lancet. 2022 Apr 2;399(10332):1313-1321. doi: 10.1016/S0140-6736(22)00151-9.
Zotero 插件